Biochemist Job Description

A biochemist works out the chemistry behind a living process and then proves it with measurements. The question might be why a mutant enzyme stops turning over its substrate, how tightly a candidate antibody grips its target, or which metabolite builds up when a pathway is blocked. BLS describes the occupation as the study of the chemical and physical principles of living things and of biological processes such as cell development, growth, heredity and disease. In practice that means making the molecule, measuring it, and writing down exactly how the number was produced so another lab can get the same one.

Basic and applied research

BLS splits the work into two kinds. Basic research has no immediate application and exists to expand knowledge. Applied research goes after a specific problem: a diagnostic test for an infection or genetic disorder, a new drug for cancer or Alzheimer's disease, a crop that tolerates drought, or a biofuel. A career can cross both. A university lab mapping how a protein changes shape can hand its assay to a company that later uses it to screen compounds.

The bench routine

A typical protein project runs through a chain. Clone or order a construct, express the protein in bacteria, insect cells or mammalian cells, purify it over a series of columns, and confirm it is folded and active. Then the real experiment: enzyme kinetics, binding measurements on instruments such as surface plasmon resonance or isothermal titration calorimetry, thermal shift assays, or mass spectrometry. O*NET's task list for the occupation includes determining the three-dimensional structure of biological macromolecules, researching the chemical effects of drugs, serums, hormones or food on tissues, and isolating, analyzing or synthesizing vitamins, hormones, allergens, minerals or enzymes. BLS adds that biochemists use lasers, fluorescent microscopes, x rays and computer modeling software, and that those in biotechnology use enzymes to synthesize recombinant DNA.

Inside a drug program

In a pharmaceutical or contract research setting, a biochemist is the person who tells the medicinal chemists whether a compound actually does what the team hopes. That means building an assay sensitive enough to rank compounds, running counter-screens to catch false positives, and working out whether an inhibitor competes with the natural substrate or binds somewhere else. The output is a table of numbers with error bars and a recommendation, and the chemists decide what to make next based on it.

Teams and data

BLS notes that most biochemists work on teams and that projects pull in physicists, chemists, computer scientists and engineers. Large data sets go to bioinformaticians, who mine them for patterns. BLS adds that some biotech products are complex enough that an expert may need to explain them to potential customers, a role it says may be more common in smaller companies, and that sales work may require a substantial amount of travel. Academic biochemists carry one more load: they write the grant applications that pay for the lab and train the students who staff it.

Degrees

The doctorate is the dividing line. BLS states that biochemists need a Ph.D. to work in independent research and development, and that bachelor's and master's degree holders qualify for some entry-level positions. As a rough guide, a bachelor's graduate starts as a research associate or lab technician running established protocols, a master's graduate takes on more method development, and a Ph.D. graduate designs the research program.

Undergraduate preparation is usually a degree in biochemistry, chemistry, biology or a related engineering field, with calculus, physics and as much lab time as the schedule allows. BLS notes that Ph.D. programs add advanced coursework in topics such as toxicology, genetics and proteomics, and that several include bioinformatics.

Program accreditation and the ASBMB exam

The American Society for Biochemistry and Molecular Biology (ASBMB) accredits B.S. and B.A. degree programs in biochemistry, molecular biology and related disciplines. Its accreditation page says applicants must show evidence of at least 400 hours of laboratory instruction. Students in an ASBMB-accredited program are invited to take the ASBMB exam in their junior or senior year, and the society says students may attempt it only once during their undergraduate career. The exam is tied to the degree program; it is not a professional license.

Postdoctoral training

BLS says many Ph.D. holders begin in temporary postdoctoral research positions, working with experienced scientists while they publish and broaden their skills. It also states that a solid record of published research is essential for a permanent college or university faculty position.

Skills worth building

• Protein production: expression in E. coli, insect and mammalian systems; affinity, ion exchange and size exclusion chromatography; quality checks by SDS-PAGE and mass spectrometry.
• Quantitative biochemistry: Michaelis-Menten kinetics, inhibition mechanisms, binding constants, dose-response fitting, and honest error analysis.
• Biophysics: surface plasmon resonance, isothermal titration calorimetry, differential scanning fluorimetry, and sample preparation for crystallography or cryo-EM.
• Computing: Python or R for data analysis, plus the habit of checking a predicted protein structure against experimental evidence before trusting it.
• Writing: grant aims, methods sections, and study reports a reviewer can follow line by line.

BLS lists analytical skill, communication, critical thinking, math including calculus and statistics, perseverance and time management as important qualities. The perseverance point is not decoration: the agency notes that scientific research involves substantial trial and error.

Safety and compliance

Labs handling pathogens, radioisotopes or toxic reagents run on written procedures, and BLS notes that workers handling dangerous organisms or toxic substances must follow safety procedures to avoid contamination. Biochemists who move toward regulated drug work also learn documentation practices that let a study stand up in a regulatory submission. Those who want to run a group can follow the path BLS describes into natural sciences management, where budgets and schedules take a larger share of the week.

The projection

BLS projects employment of biochemists and biophysicists to grow 12 percent from 2025 to 2035, much faster than the average for all occupations. The agency counts 35,200 jobs in 2025 and projects 39,500 in 2035, with about 2,900 openings a year on average across the decade. BLS expects many of those openings to come from replacing workers who change occupations or leave the labor force. The agency ties demand to biomedical research for an aging population, genetic research, new medicines, diagnostic tests, and biotechnology work in clean energy, food production and environmental protection.

BLS places 61 percent of the occupation in scientific research and development services, 17 percent in pharmaceutical and medicine manufacturing, 5 percent in state colleges, universities and professional schools, and 3 percent in self-employment.

FDA is rewriting the preclinical playbook

For biochemists in drug development, one concrete change since 2025 is regulatory. FDA's April 2025 roadmap set out to reduce animal testing in preclinical safety studies, and the agency followed with draft guidance. On Dec. 2, 2025, it issued draft guidance outlining product types for which FDA believes six-month non-human primate toxicity testing of monoclonal antibodies can be eliminated or reduced; FDA said a typical antibody program could use more than 100 non-human primates at approximately $50,000 per animal. On March 18, 2026, FDA issued draft guidance on validating new approach methodologies (NAMs) with four core principles: context of use, human biological relevance, technical characterization and fit for purpose. Its examples include organoids, organs on chips, chemical reactivity studies and in silico modeling.

On April 20, 2026, FDA said it had met its key first-year goals, launched a searchable database showing where alternative methods are acceptable, and set up a formal partnership with the National Institutes of Health. Human-relevant assays of that kind have to be built, validated and defended with data, which is core biochemistry work.

Academic funding is tighter

BLS notes that biochemists doing basic research typically must submit grant proposals to universities, foundations and the federal government to fund their work. At NIH, the numbers moved. A Congressional Research Service report updated April 17, 2026 says NIH research project grant success rates fell to 13 percent in FY2025 from 19 percent in FY2024, while applications rose 13 percent. CRS says NIH's policy of funding some grants up front for all years of the project likely contributed to fewer awards, and that the rise in applications may also partially explain the lower success rates. The FY2026 appropriations law, P.L. 119-75, limits multiyear award obligations to the FY2025 level and continues a bar on changing NIH indirect cost policy. As of that report, the 2025 NIH indirect cost policy was enjoined, a decision upheld on appeal in January 2026.

NIH also changed the application rules. Its notice NOT-OD-25-132 says the agency will accept only six new, renewal, resubmission or revision applications from an individual principal investigator in a calendar year, effective with the Sept. 25, 2025 receipt date.

AI and automation

Computation is part of the job description, not a side topic. ASBMB's fall 2025 preview of its 2026 annual meeting (March 7-10, outside Washington, D.C.) listed an extended deep-dive session on AI called "I, biochemist: Automation and AI in the lab," and FDA's year-one report says the agency qualified its first artificial intelligence-based drug development tool. Neither changes the need for wet-lab proof: a predicted structure or a model's call still has to be checked against an assay.

Dear Hiring Manager,

Your posting for a Biochemist on the protein sciences team caught my attention right away. I finished my Ph.D. in biochemistry at a state university, where I studied how a bacterial dehydrogenase changes shape when its cofactor binds, and I have spent the last two years as a postdoctoral fellow building assays for a small enzyme drug discovery group.

Most of my work starts with getting good protein. During my postdoc I rebuilt our expression and purification workflow for a membrane-associated enzyme that had stalled the project for a year. By switching to an insect cell system, adding a detergent screen and tightening the size exclusion step, I produced batches that held activity for weeks instead of days. That material made it possible to run the first full kinetic characterization of the target, and the inhibition data I generated now guides which compound series the chemists pursue.

I also care about the parts of the job that are easy to skip. I write methods sections that a new technician can follow, I log lot numbers and instrument settings for every run, and I treat a computational structure prediction as a hypothesis to test, not an answer. When a binding result looked too good last spring, I traced it to a buffer artifact before it reached the project review.

Your team's focus on enzyme targets with difficult assays is the reason I am writing. I would bring hands-on skill with surface plasmon resonance, thermal shift and steady-state kinetics, along with experience mentoring two technicians through their first independent experiments.

Thank you for your time. I would welcome a conversation about the assays your group is building next.

Sincerely, Jordan Ellery